Skip to content
lifestyle.careersavvy.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Celcuity Inc.
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
October 24, 2026
Celcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
October 23, 2026
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
October 8, 2026
Celcuity Appoints David Gryska To Its Board Of Directors
October 7, 2026
Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
September 30, 2026
Celcuity To Participate in Upcoming Investor Conferences
September 1, 2026
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
August 26, 2026
Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
August 17, 2026
Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call
August 6, 2026
Newly FDA-Approved REVTORPYK™ (gedatolisib) Included in the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines for HR+/HER2- Locally Advanced or Metastatic Breast Cancer
July 30, 2026
1
2
3
Next Page
→